biological source
human lung
packaging
tube of 5 μg 96042328-DNA-5UG, pkg of vial of cells 96042328-1VL
growth mode
Aggregates in suspension
karyotype
Not specified
morphology
Not specified
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Application
Drug-resistance studies, small cell lung cancer
Biochem/physiol Actions
Human small cell lung cancer, drug-resistant
NCI-H69/CPR is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802). Drug resistance was developed by addition of a stepwise increase in cisplatin to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. A significant change in cellular glutathione content or sensitivity to cadmium chloride (as indicator of metallothionein content) was not detected, but changes in glutathione-S-transferase activity were seen. Cisplatin accumulation was unchanged compared with the parent line. It is recommended to culture the cells without drugs after resuscitation until the first passage.
Preparation Note
Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37ºC; resuscitate in drug-free medium until first passage.
RPMI 1640 + 2mM Glutamine + 0.4μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
法规信息
低风险生物材料
常规特殊物品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持